Factors associated with poor prognosis of IDH wild gliomas

In 2016, WHO classified central nervous system tumors molecularly, classifying low-grade glioma (LGG) into IDH mutation and IDH wild type according to the mutation state of isocitric acid dehydrogenase (IDH)Kiyonori Kuwahara, of Neurosurgery at Fujita Medical University Hospital in Japan, and others further classified the idh wild-type LGG with molecular genes to expand the subclassifications that can be used to predict the prognosisof the studycollected records of age, KPS score, PRE- and post-surgery MRI scan results, presence of calcification and lesions in lesions in 41 cases of idh wild diffuse atrophatoma and intersasexual asocytoma between 2004 and 2018Frozen slicing of tumor samplesExtractdna analysis of chromosome 7 multipliers (-7) or chromosome 10 deletions (-10q) status, using PCR chain reaction to obtain IDH1/2, BRAF, TERTp and H3F3A mutation dataAtRX mutations and MIB-1 indices were analyzed using immunohistosisThe Kaplan-Meier method, which is used as a platform in the R language, makes a statistical assessment of the factors that affect the prognosisresults41 patients included 8 idh wild diffuse astrocyma (WHO class II), 27 idh wild transsexual adenoid atomoma (WHO III) and 6 cases of yellow astrocyma and polymorphic yellow astrocyma; After surgery, 28 patients received temequina, pyrethofa or nimostin chemotherapy, and 26 patients received radiotherapyThe median survival of35 patients was 28.9 monthsThe Kaplan-Meier method single-factor analysis showed that the pathological credit type, the difference in the number of chromosome copies (-7, -10q) and the TERT promoter mutation affected the prognosis of the patient, with significant differences in resultsMulti-factor analysis showed that differences in chromosomal copy numbers (-7, -10q) and TERT promoter mutations were independent risk factors for poor prognosisconclusionsresults showed that in WHO Grade II and III gliomas, patients with tumors with mutations of plus 7, -10q or TERTp had significantly shorter survival terms than those without the mutationPrevious studies have reported that the IDH wild-type LGG prog prognosis and clinical manifestations with chromosome 7 multipliers (-7) and chromosome 10 (-10q) are similar to those with glioblastomas with a level of 7/-10q, which the researchers refer to as "7/10." in this study, none of the idh wild LGG cases did simultaneously with the mutations of -7, -10q and TERTp However, further tests showed that there were three simultaneous mutations in about 50% of glioblastoma cases; In predicting the prognosis of IDH wild LGG, the use of molecular subclassification is more accurate than WHO classification, which helps to identify patients with poor prognosis in advance and to provide early complementary treatment.